tbuckley/cabot-search huggingface dataset:
Detection and prevalence of IUD-associated Actinomyces colonization and related morbidity. A prospective study of 69,925 cervical smears
Authors: J. F. Valicenti
Journal: JAMA (1982)

Cervical Papanicolaou smears from 69,925 women were screened prospectively for the presence of<i>Actinomyces israelii</i>. The organism was not identified in non-intrauterine (contraceptive) device (IUD)-wearers. The prevalence of<i>A israelii</i>among IUD wearers ranged from 1.6% (general population) to 5.3% (clinic population). Protracted IUD use seemed to predispose to a higher incidence of infection. Direct immunofluorescence proved to be a more accurate and specific method of identification when compared with conventional light microscopy and anaerobic culture. Two of 112 women with direct immunofluorescence-proved<i>A israelii</i>had significant clinical infections. It appears that in the vast majority of cases, IUD-associated<i>Actinomyces</i>colonization produces only a superficial infestation. Conservative management is suggested for asymptomatic patients with cytologically detected<i>Actinomyces</i>to include removal of the IUD and repeated Papanicolaou smear after the next menstrual period. (<i>JAMA</i>1982;247:1149-1152)
Impact of oncology drug shortages.
Authors: Ezekiel J. Emanuel, Katie Shuman, Derek Chinn, Keerthi Gogineni
Journal: Journal of Clinical Oncology (2013)

CRA6510 Background: Drug shortages of common chemotherapeutics have been reported. What is the prevalence and consequence of these shortages? Methods: Between 9/2012 and 1/2013, a self-administered questionnaire was sent to a random sample of 455 board-certified U.S. oncologists selected from the American Society of Clinical Oncology directory to assess the prevalence of shortages and impact on therapeutic decision-making. 245 responses were received (response rate 55%), of whom 210 were practicing medical oncologists/hematologists. Results: Due to drug shortages in the prior 6 months, 92% (163) of oncologists reported that their patients’ treatment was affected and 83% (174) were unable to prescribe standard chemotherapy. The five chemotherapy agents most commonly reported in shortage were: leucovorin (68%), liposomal doxorubicin (63%), 5-FU (19%), bleomycin (18%), and cytarabine (17%). Physicians adapted in many ways. 38% of the time, oncologists substituted more expensive branded drugs for those in shortage, such as levoleucovorin for leucovorin. Nearly 13% of the time, shortages prevented enrollment, delayed administration of a study drug, or suspended involvement of patients on clinical trials. Despite the prevalence of scarcities, 70% (146) of oncologists reported their cancer centers or practices lacked formal guidance for allocation decisions. Conclusions: Drug shortages in oncology are very common, compromise the delivery of standard care, impede research, and lead to higher costs by using branded drugs instead of generics. Oncologists also seem to lack formal guidance on how to address these shortages. [Table: see text]
AMA-RPS Due Process Report
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft
Authors: Naji Aldosari, Rodney N. Wiltshire, Amalia Dutra, Evelin Schrock, Roger E McLendon, Henry S. Friedman, Darell D. Bigner, Sandra H. Bigner
Journal: Neuro-Oncology (2002)

Neuro-OncologyCell lines and xenografts derived from medulloblastomas are useful tools to investigate the chromosomal changes in these tumors.Here we used G-banding, uorescence in situ hybridization (FISH), spectral karyotyping (SKY), and comparative genomic hybridization to study 4 medulloblastoma cell lines and 1 xenograft.Cell line D-425 Med had a relatively simple karyotype, with a terminal deletion of 10q and ampli cation of MYC in double-minutes (dmins).FISH demonstrated that an apparent isochromosome (17q) by routine karyotyping was actually an unbalanced translocation between 2 copies of chromosome 17.Cell line D-556 Med also had a simple near-diploid stemline with an unbalanced 1;13 translocation resulting in a gain of 1q, an isochromosome (17q), and dmins.These ndings were initially described using routine G-banded preparations, and FISH showed that the dmins were an ampli cation of MYC and the i(17q) was an isodicentric 17q chromosome.The other nding was con rmed by FISH, SKY, and comparative genomic
Misoprostol and Gastrointestinal Complications in Patients Taking Nonsteroidal Anti-Inflammatory Drugs for Rheumatoid Arthritis
Authors: Fred E. Silverstein
Journal: Annals of Internal Medicine (1996)

Letters15 May 1996Misoprostol and Gastrointestinal Complications in Patients Taking Nonsteroidal Anti-Inflammatory Drugs for Rheumatoid ArthritisFred E. Silverstein, MD and G. Steven Geis, PhD, PhD, MDFred E. Silverstein, MDUniversity of Washington Medical School, Seattle, WA 98195G. D. Searle & Co. Skokie, IL 60077Search for more papers by this author and G. Steven Geis, PhD, PhD, MDUniversity of Washington Medical School, Seattle, WA 98195G. D. Searle & Co. Skokie, IL 60077Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-10-199605150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the responses to our article [1]. We agree that the concept of NNT raised by Dr. Wendel and by Madhok and colleagues is important. Using the formula NNT = 1/(riskplacebo − riskmisoprostol), we determined that the NNT was 263 for the 67 serious NSAID-related gastrointestinal events we observed. For those patients at higher risk, however, the NNT to avert a gastrointestinal complication becomes much smaller. For example, for patients with previous peptic ulcer disease, the NNT is 53.We recently completed additional analyses of the 242 events reported as suspected NSAID-induced complications. These events include patients ...References1. Silverstein FE, Graham DY, Senior JR, Wyn Davies H, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:241-9. Google Scholar2. Simon LS, Polisson RP, Hatoum HT, Bittman RM. Risk factors for serious nonsteroidal induced GI complications: the risk reduction effect of misoprostol therapy in the individual “at-risk” patient. Arthritis Rheum. 1995; 38(Suppl):S206. Google Scholar3. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995; 123:344-50. Google Scholar Author, Article, and Disclosure InformationAuthors: Fred E. Silverstein, MD; G. Steven Geis, PhD, PhD, MDAffiliations: University of Washington Medical School, Seattle, WA 98195G. D. Searle & Co. Skokie, IL 60077 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 May 1996Volume 124, Issue 10Page: 927KeywordsDrugsHealth care utilizationHemorrhageHospitalizationsNSAIDsNumber needed to treatPeptic ulcersPopulation statisticsRheumatoid arthritisUlcers ePublished: 15 August 2000 Issue Published: 15 May 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
MDM2 Protein Overexpression Inhibits Apoptosis of TF-1 Granulocyte-Macrophage Colony-Stimulating Factor–Dependent Acute Myeloblastic Leukemia Cells
Authors: Mitsuyoshi Urashima, Gerrard Teoh, Dharminder Chauhan, Atsushi Ogata, Shuya Shirahama, Chiharu Kaihara, Masaharu Matsuzaki, Hiroshi Matsushima, Masaharu Akiyama, Youki Yuza, Kihei Maekawa, Kenneth C. Anderson
Journal: Blood (1998)
BRAF-V600E Mutation on Circulating Cell-Free DNA Is a Promising Biomarker of High-Risk Adult Langerhans Cell Histiocytosis
Authors: Masayuki Kobayashi, Nobuhiro Ohno, Tomofusa Fukuyama, Toyotaka Kawamata, Kaoru Uchimaru, Arinobu Tojo
Journal: Blood (2014)
The elusive generalist physician. Can we reach a 50% goal?
Authors: D. A. Kindig
Journal: JAMA (1993)

National attention has focused on the goal of attaining 50% primary care practitioners to facilitate patient access and cost-effectiveness. To determine how long it might take to achieve this goal, we used the Bureau of Health Professions' aggregate physician supply model to forecast the generalist-specialist balance. Assuming that 30% of graduates will enter generalist practice after 1993 (the percentage in the mid-1980s), the number of generalists would increase from 174 940 in 1990 to 232 000 in 2040 (77 per 100 000 population), but the percentage would remain at about 30%; specialists would continue to make up about 70% of all active physicians, but their total number would grow from 345 600 to 537 000 (178 per 100 000 population). If 50% of graduates were to enter generalist practices, by the year 2040 the number of generalists would grow to 373 000, or 124 per 100 000 (48.4% of all physicians). If entry into generalist practice falls to 20%, as suggested by recent medical student preferences, the number of generalists would peak at 192 000 (26.4%) in 2010 and would fall to 160 000 (21%) by 2040, resulting in 53 generalists and 201 specialists per 100 000 population. We discuss the implications of these findings on aggregate physician supply and on policy initiative affecting the ratio of generalists to specialists. Reform proposals affecting the specialty mix should clearly identify the desired future ratio of generalists and specialists per capita. (<i>JAMA</i>. 1993;270:1069-1073)
Bilateral adrenal hemorrhage in an adult. Demonstration by computed tomography
Authors: S. G. Albert
Journal: JAMA (1982)

ACUTE bilateral adrenal hemorrhage has been reported in postoperative patients,<sup>1</sup>in patients with hemorrhagic diatheses,<sup>2,3</sup>and in association with severe stress and hypotension.<sup>4</sup>The diagnosis is considered infrequently before death because symptoms may be masked or ascribed to more common clinical conditions. Twelve days after an uncomplicated surgical procedure, a patient with a mild hemorrhagic diathesis experienced acute bilateral adrenal hemorrhage. The symptoms and signs were initially ascribed to more common postoperative complications. The routine laboratory evaluation results did not suggest adrenal insufficiency. The diagnosis of acute adrenal hemorrhage and adrenal insufficiency was suggested by computed tomography (CT) and confirmed by a cosyntropin stimulation test. <h3>Report of a Case</h3> A 46-year-old man was admitted for removal of an accessory spleen because of thrombocytopenia. A diagnosis of poorly differentiated lymphocytic lymphoma, stage 3B, had been made four years earlier. Splenectomy had been performed at the initial staging laparotomy.
Asbestos-Induced Lung Disease
Authors: Arnold R. Brody
Journal: Environmental Health Perspectives (1993)

This review attempts to deal with two major questions concerning asbestos-induced lung disease: How does inhaled asbestos cause cell proliferation and fibrosis? and Will there continue to be risk from exposure to asbestos in schools and public buildings? The first is a scientific question that has spawned many interesting new experiments over the past 10 years, and there appear to be two hypothetical schemes which could explain, at least in part, the fibroproliferative effects of asbestos fibers. One supports the view that toxic oxygen radicals generated on fiber surfaces and/or intracellularly are the central mediators of disease. The second hypothesis is not mutually exclusive of the first, but, in my opinion, may be integral to it, i.e., the cellular injury induced by oxygen radicals stimulates the elaboration of multiple varieties of growth factors and cytokines that mediate the pathogenesis of asbestosis. There is increasing evidence that molecules such as platelet-derived growth factor and transforming growth factor beta, both synthesized and secreted by activated lung macrophages, are responsible, respectively, for the increased interstitial cell populations and extracellular matrix proteins that are the hallmarks of asbestos-induced fibrosis. The challenge today is to establish which combinations of the many factors released actually are playing a role in disease pathogenesis. The issue of continued risk currently is more a question of policy and perception than science because a sufficient database has not yet been established to allow full knowledge of the circumstances under which asbestos in buildings constitutes an ongoing health hazard. The litigious nature of this question does not help its resolution. In as much as public policy statements and risk assessment are not within my purview, I have focused on the state-of-the-art of asbestos as a complete carcinogen. It appears to be generally nongenotoxic, but all asbestos fiber types can induce chromosomal mutations and aneuploidy, perhaps through their ability to disrupt normal chromosome segregation.
Name Misspelled
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7.
Authors: S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. R. C. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton
Journal: Journal of Clinical Oncology (2011)

CRA9015 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
TUBERCULOSIS AND MILK.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: BMJ (1902)

a' Queries, answers, and communications relating to subjects to which special departments of the BRITISH MEDICAL JOURNAL are devoted will be found under their respective headings. QIERIES.MEDICAL PRACTITIONER asks: Is there any philantlhropiC institution (preferably in the North of England), not an almshouse, where an invalid lady in reduced circumstanees, requiring some nursing, could be admitted for a lengthened period as a patient, though unable to pay more than £ 15 to £20 a year?A CORRESPONDENT writes that he is an assistant in receipt of £ico per annum, but that he has also private means, so that this salary comes under assessment for income tax.His principal, in returning deduc- tions from income tax, puts expenses of assistaiut at £200 per annum- namely, £Ioo for salary and x0oo for board, etc.He wishes to know wvhether he has to pay on the £ioo received, or on the £2CO returned by his principal.*** Our correspondent need not trouble about his principal's return.He will probably receive a demand assessed on
Table of Contents
Authors: John Harrington, Andrew Levey, Nicolaos Madias, Christina Wyatt, Stephen Textor, Luca Perico, Ariela Benigni, Daisuke Nakano, Akira Nishiyama, Emanuele Cozzi, Luigi Biancone, Patrick Nachman, Patrick Parfrey, Michel Jadoul, Marina Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram Kasiske, Ching-Lung Lai, José Morales, Priti Patel, Stanislas Pol, Marcelo Silva, Ethan Balk, Craig Gordon, Amy Earley, Mengyang Di, Paul Open, Manish Saha, Bruce Julian, Jan Novak, Dana Rizk, Marc Ghannoum, Robert Hoffman, Sophie Gosselin, Thomas Nolin, Valery Lavergne, Darren Roberts, Zivile Békássy, Ann-Charlotte Kristoffersson, Johan Rebetz, Ramesh Tati, Anders Olin, Diana Karpman, Natsuko Tokonami, Tomoaki Takata, Jan Beyeler, Iris Ehrbar, Ayumi Yoshifuji, Erik Christensen, Johannes Loffing, Olivier Devuyst, Eric Olinger Open, Shunsuke Yamada, Elizabeth Leaf, Jia Chia, Timothy Cox, Mei Speer, Cecilia Giachelli, Tanvi Arkatkar, Holly Jacobs, Samuel Du, Quan-Zhen Li, Kelly Hudkins, Charles Alpers, David Rawlings, Shaun Jackson, Anja Thorenz, Katja Derlin, Christoph Schröder, Lisa Dressler, Vijith Vijayan, Pooja Pradhan, Stephan Immenschuh, Anne Jörns, Frank Echtermeyer, Christine Herzog, Rongjun Chen, Song Rong, Jan Bräsen, Cees Van Kooten, Torsten Kirsch, Christian Klemann, Martin Meier, Andreas Klos, Hermann Haller, Bennet Hensen, Faikah Gueler, Lili Zhou, Shan Zhou, Peng Yang, Yuan Tian, Zhiwei Feng, Xiang-Qun Xie, Youhua Liu, Denis Viglietti, Yassine Bouatou, David Kheav, Olivier Aubert, Caroline Suberbielle-Boissel, Denis Glotz, Christophe Legendre, Jean-Luc Taupin, Adriana Zeevi, Alexandre Loupy, Carmen Lefaucheur, Marcelo De Rosa, Francisco Azzato, Jorge Toblli, Graciela De Rosa, Federico Fuentes, Haikady Nagaraja, Ryan Nash, Brad Rovin
Journal: Kidney International (2018)
ICELAND
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal